Dayvigo (Lemborexant) Cost in Vermont: Prices, Insurance, and Savings for 2026

Lemborexant, marketed as Dayvigo, is an oral dual orexin receptor antagonist (DORA) that received FDA approval in December 2019 to treat insomnia in adults who experience problems with sleep initiation or sleep maintenance. Although lemborexant shares the DORA class with suvorexant (Belsomra) and daridorexant (Quviviq), each medication carries its own distinct FDA approval, prescribing label, and cost structure. The DEA classifies lemborexant as a Schedule IV controlled substance.

What is established: Dayvigo has a manufacturer-published list price that is higher than what most insured patients actually pay, Vermont Medicaid can cover it but generally requires prior authorization documenting a prior trial of a first-line insomnia medication, and a manufacturer copay savings program exists for commercially insured patients but does not apply to Medicaid, Medicare, or other government coverage. What is not established on this page: the exact current dollar figures for list price, average Vermont cash price, specific copay tiers by insurer, and the manufacturer savings card's annual cap, because these numbers change over time and were not confirmed against a dated primary source for this draft. Anyone using this page to budget should verify current numbers directly before assuming they apply.

The direct answer, with its boundaries

Dayvigo's manufacturer list price is set independently by Eisai and published on the company's pricing pages; it is materially higher than what most patients with insurance, a discount card, or the manufacturer savings program actually pay at the register. Vermont Medicaid (administered through the Department of Vermont Health Access) treats newer insomnia drugs like DORAs as non-preferred in many state programs and typically requires prior authorization showing a documented trial of a generic first-line agent, a pattern consistent with how state Medicaid programs generally manage this drug class, though Vermont's current preferred drug list should be checked directly since formularies change during the plan year. Compounded lemborexant can legally be dispensed by a licensed 503A pharmacy with a valid patient-specific prescription under the federal Drug Quality and Security Act framework, but compounded versions are not FDA-approved and have not undergone the bioequivalence testing that the manufactured tablet has.

What Dayvigo costs in Vermont: what's stable and what changes

Two different numbers get conflated in most discussions of drug cost: the manufacturer's list price and what a given patient actually pays. The list price is a real, publicly stated figure, but it is rarely what anyone pays out of pocket once insurance, pharmacy benefit manager contracts, discount cards, or manufacturer assistance are applied. Cash prices at individual pharmacies also vary by location, by which discount network the pharmacy participates in, and by month, since these are negotiated and can shift.

Because this specific draft could not confirm a dated, sourced figure for either Dayvigo's current list price or the average Vermont retail cash price, we are not printing a specific dollar amount here. If a prior version of this page stated a precise number (for example, a specific list price or a specific average Vermont cash price), treat that number as unverified until it is checked against Eisai's current pricing disclosure or a live pharmacy quote. The practical path for a reader is to call two or three Vermont pharmacies directly, or check a pharmacy pricing tool, on the date you intend to fill the prescription.

Vermont Medicaid coverage

Vermont Medicaid can cover Dayvigo, but coverage in most state Medicaid programs for newer branded insomnia drugs is conditioned on prior authorization. The general pattern, consistent across many states' Medicaid preferred drug lists, is that a prescriber must document that the patient tried, failed, or has a contraindication to a first-line generic option (commonly zolpidem, or trazodone used off-label for insomnia) before a DORA like lemborexant is approved.

Vermont's specific preferred drug list, prior authorization criteria, and turnaround times for PA decisions are set by the Department of Vermont Health Access and its contracted pharmacy benefit manager, and these details can change during a plan year. This page does not have a confirmed, dated source for Vermont's current PA criteria or appeal timelines, so a prescriber's office or the DVHA member services line should be consulted for the current requirement before assuming a specific process or timeline applies.

Commercial insurance and Medicare Part D

Commercial insurers operating in Vermont maintain their own formularies, and tier placement for Dayvigo (preferred brand, non-preferred brand, or specialty) differs by plan and can change annually. The most reliable way to know what a specific plan will charge is to call the member services number on the insurance card and ask the pharmacy benefit team for the formulary status, tier, and any prior authorization or step therapy requirement tied to lemborexant.

Medicare Part D plans generally include coverage pathways for FDA-approved insomnia medications, though placement often falls on a non-preferred or specialty tier with a higher copay. The FDA-approved prescribing information establishes the approved indication (insomnia with difficulty of sleep onset and/or maintenance in adults), which is the basis a prescriber would cite in a medical necessity letter if a Part D plan initially denies coverage.

Verification checklist: what's stable versus what you must check fresh

Cost and coverage information for a branded prescription drug splits cleanly into two categories: facts that are set at the federal or clinical level and don't change month to month, and facts that are set by an insurer, state agency, or individual pharmacy and can change at any time. Before making a financial decision based on any Dayvigo pricing claim, sort it into one of these two buckets.

Stable facts (verify once, unlikely to have changed recently):

• Lemborexant's FDA approval (December 2019) and its approved indication for insomnia in adults, confirmable at accessdata.fda.gov
• Lemborexant's DEA Schedule IV controlled substance status
• The mechanism of action (dual orexin receptor antagonism, OX1R/OX2R)
• The starting dose framework described in the label (lowest effective dose taken at bedtime with adequate time before waking) and the label's narcolepsy warning
• The legal framework allowing 503A pharmacies to compound patient-specific prescriptions under the federal Drug Quality and Security Act, described at fda.gov

Date-sensitive facts (re-verify at the time you need them, do not rely on a prior draft's number):

• Eisai's current list price for Dayvigo
• Current average cash price at any specific Vermont pharmacy
• Vermont Medicaid's current preferred drug list placement and prior authorization criteria for Dayvigo
• Any specific commercial insurer's formulary tier, copay amount, or step therapy rule for lemborexant
• The Eisai savings card's current eligibility rules, dollar cap, and whether it counts toward a deductible under a given plan's accumulator policy
• Compounding pharmacy pricing and current Vermont Board of Pharmacy licensing status for any specific compounder
• State telehealth and DEA controlled-substance prescribing rules, since federal telehealth flexibilities for controlled substances have been extended and modified more than once since 2020

If a number in this article, or any other source, is not dated to a specific month and year, treat it as a starting point for a phone call rather than a fact to budget around.

The Eisai savings card: how it generally works

Eisai has offered a manufacturer copay savings program for Dayvigo aimed at commercially insured patients. Like most manufacturer copay cards, it is not available to patients on Medicaid, Medicare, TRICARE, or other government-funded coverage, and it works by covering some or all of the gap between a plan's copay and a promotional price, up to an annual cap set by the manufacturer. The specific dollar amounts, income eligibility, and annual maximum for this program change periodically, so the current terms should be confirmed on Eisai's own program page or through a prescriber's office rather than assumed from a prior year's figure.

One detail worth asking about directly: some insurers use copay accumulator or maximizer programs that prevent manufacturer copay assistance from counting toward a deductible or out-of-pocket maximum. Whether this applies depends on the specific health plan, not on Vermont law generally, so this is a question for the plan administrator rather than something this page can state as fixed.

Compounded lemborexant

Compounded lemborexant can be dispensed through a licensed 503A compounding pharmacy with a valid, patient-specific prescription when a prescriber identifies a clinical need, such as a strength that is not commercially manufactured. This is governed by the federal Drug Quality and Security Act (2013), and state pharmacy boards, including Vermont's, oversee compounding pharmacy licensing and inspection.

Compounded formulations are not FDA-approved. They have not undergone the bioequivalence testing that the manufactured Dayvigo tablet has, and potency can vary batch to batch depending on the compounding pharmacy's quality controls. The FDA's compounding guidance describes compounded drugs as products that have not been evaluated by the FDA for safety, effectiveness, or quality in the way an approved drug has been, which is a meaningful distinction for a controlled substance where consistent dosing matters. Anyone considering a compounded version instead of the brand or an insurance-covered generic alternative should discuss the trade-offs, including the lack of FDA bioequivalence review, with the prescribing clinician before switching. Verify that any specific compounding pharmacy holds a current, active Vermont pharmacy license before using it.

Telehealth prescribing in Vermont

Vermont allows licensed clinicians to prescribe controlled substances, including Schedule IV medications like Dayvigo, through telehealth visits, subject to the prescriber holding a valid Vermont license and DEA registration and using electronic prescribing for controlled substances (EPCS), which Vermont requires for Schedule II through V prescriptions. Federal telehealth flexibilities that allow prescribing certain controlled substances without a prior in-person visit have been extended multiple times since 2020, and the current federal rule status should be checked at the time of a visit rather than assumed to be permanent.

A typical telehealth insomnia evaluation includes a sleep history, screening for obstructive sleep apnea and other sleep disorders, a review of current medications for interactions, and a discussion of alternatives, including cognitive behavioral therapy for insomnia (CBT-I), which the American Academy of Sleep Medicine and other guideline bodies generally recommend as a first-line approach for chronic insomnia, with medication considered when CBT-I is unavailable, insufficient, or the patient prefers a medication trial.

How lemborexant compares with other insomnia options on cost, in general terms

Dayvigo sits within a small class of branded DORAs that also includes suvorexant (Belsomra) and daridorexant (Quviviq). These three drugs are generally priced closer to each other than to older, long-generic insomnia medications like zolpidem or trazodone, which are typically far less expensive because they have been available in generic form for years. This draft does not have a confirmed, dated comparison of current list prices across all three DORAs, so specific numbers should be checked directly rather than assumed from any single source, including this one.

The clinical trade-off is not only price. Older agents like zolpidem and trazodone work through different mechanisms (GABA-A modulation and serotonin antagonism, respectively) and carry different risk profiles, including next-day sedation, complex sleep behaviors, and dependency concerns with Z-drugs. DORAs were developed in part to reduce some of these risks by targeting the wake-promoting orexin pathway rather than broadly sedating the brain, an approach supported by trial evidence in adults, including older adults, though DORAs carry their own warnings, discussed below.

Ways to lower out-of-pocket cost

A few approaches are worth discussing with a prescriber or pharmacist regardless of the exact current price:

1. If commercially insured, ask about the Eisai savings program's current terms before filling.
2. If uninsured, ask the pharmacy to run a current discount card price alongside the cash price, since these are negotiated and can differ pharmacy to pharmacy.
3. If on Vermont Medicaid, have documentation ready for prior authorization: the specific generic tried, the dose, the duration, and the reason it was discontinued or insufficient.
4. Ask about a manufacturer patient assistance program if uninsured or underinsured; eligibility is generally income-based and applications typically go through the prescribing office, but current income thresholds should be confirmed with the manufacturer directly.
5. Ask whether a 90-day supply reduces the number of copays owed under the specific plan, since many plans charge fewer copays for a 90-day fill than three separate 30-day fills, though this benefit design varies by plan.

Clinical considerations before starting Dayvigo

Lemborexant blocks orexin receptors OX1R and OX2R, suppressing the brain's wake-promoting signal rather than broadly sedating it, which is the mechanistic rationale for this drug class. In trial data described in the FDA label, the most common adverse effects included somnolence, headache, and, less commonly, sleep paralysis; the FDA label documents higher rates of next-day somnolence at the 10 mg dose compared with placebo, and the exact percentages should be checked against the current label rather than an older summary.

Because DORAs act on the same orexin pathway that is deficient in narcolepsy, the FDA label carries a warning against use in patients with narcolepsy, and prescribers are expected to screen for this before initiating treatment. Lemborexant is metabolized by CYP3A4, and the label describes contraindications with strong CYP3A4 inhibitors and dose adjustment recommendations with moderate inhibitors; anyone on multiple medications should have an interaction check run by the prescriber or pharmacist rather than relying on a general list. The typical starting approach described in the label is the lowest effective dose taken immediately before bedtime with adequate time remaining before the person needs to wake, with dose increases considered only if the starting dose is tolerated but insufficiently effective; doses above the highest approved dose have not been studied and should not be used.

This is general education, not individualized dosing guidance. Anyone with sudden new-onset severe daytime sleepiness, signs of complex sleep behavior (activities performed while not fully awake, such as driving), or worsening depression or suicidal thoughts while on this medication should contact their prescriber promptly or seek urgent care.